TWI870839B - 可用於降尿酸的化合物 - Google Patents

可用於降尿酸的化合物 Download PDF

Info

Publication number
TWI870839B
TWI870839B TW112115878A TW112115878A TWI870839B TW I870839 B TWI870839 B TW I870839B TW 112115878 A TW112115878 A TW 112115878A TW 112115878 A TW112115878 A TW 112115878A TW I870839 B TWI870839 B TW I870839B
Authority
TW
Taiwan
Prior art keywords
group
alkyl
substituted
compound
nitrile
Prior art date
Application number
TW112115878A
Other languages
English (en)
Chinese (zh)
Other versions
TW202342456A (zh
Inventor
東方 史
傅長金
楊豔
李海明
袁承詣
Original Assignee
大陸商杭州新元素藥業有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 大陸商杭州新元素藥業有限公司 filed Critical 大陸商杭州新元素藥業有限公司
Publication of TW202342456A publication Critical patent/TW202342456A/zh
Application granted granted Critical
Publication of TWI870839B publication Critical patent/TWI870839B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TW112115878A 2022-04-27 2023-04-27 可用於降尿酸的化合物 TWI870839B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202210456939 2022-04-27
CN2022104569393 2022-04-27

Publications (2)

Publication Number Publication Date
TW202342456A TW202342456A (zh) 2023-11-01
TWI870839B true TWI870839B (zh) 2025-01-21

Family

ID=87872273

Family Applications (1)

Application Number Title Priority Date Filing Date
TW112115878A TWI870839B (zh) 2022-04-27 2023-04-27 可用於降尿酸的化合物

Country Status (6)

Country Link
US (1) US20250282753A1 (enExample)
EP (1) EP4516781A4 (enExample)
JP (1) JP7792730B2 (enExample)
CN (1) CN116715633B (enExample)
TW (1) TWI870839B (enExample)
WO (1) WO2023208108A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119241538A (zh) * 2024-09-30 2025-01-03 陕西科技大学 一类三唑并吡啶结构的化合物、合成方法及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201118077A (en) * 2009-10-07 2011-06-01 Lg Life Sciences Ltd Novel compounds effective as xanthine oxidase inhibitors, method for preparing the same, and pharmaceutical composition containing the same
CN115160299A (zh) * 2021-04-29 2022-10-11 江苏新元素医药科技有限公司 一类黄嘌呤氧化酶抑制剂

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050090529A1 (en) * 2003-07-31 2005-04-28 Pfizer Inc 3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation
MX2008001778A (es) * 2005-08-19 2008-04-07 Aventis Pharma Inc Combinacion de un agente hipnotico y un compuesto de bis arilo y heteroarilo sustituido y aplicacion terapeutica de la misma.
CA2623327A1 (en) * 2005-10-07 2007-04-19 Kissei Pharmaceutical Co., Ltd. Nitrogenated heterocyclic compound and pharmaceutical composition comprising the same
JPWO2010044403A1 (ja) * 2008-10-15 2012-03-15 キッセイ薬品工業株式会社 ５員環ヘテロアリール誘導体及びその医薬用途
WO2010044404A1 (ja) * 2008-10-15 2010-04-22 キッセイ薬品工業株式会社 縮合複素環誘導体及びその医薬用途
WO2010093191A2 (en) * 2009-02-13 2010-08-19 Lg Life Sciences Ltd. Novel compounds effective as xanthine oxidase inhibitors, method for preparing the same, and pharmaceutical composition containing the same
JP5990106B2 (ja) * 2011-01-28 2016-09-07 佐藤製薬株式会社 縮環化合物
TWI548630B (zh) * 2011-04-06 2016-09-11 Ｌｇ生命科學有限公司 １－（３－氰基－１－異丙基－吲哚－５－基）吡唑－４－羧酸結晶型及其製造方法
KR20150138212A (ko) * 2013-03-29 2015-12-09 데이진 화-마 가부시키가이샤 피라졸 유도체
CN105439946B (zh) * 2014-08-13 2018-02-02 益方生物科技（上海）有限公司 羧酸化合物及其制备方法和用途
KR20170105021A (ko) * 2015-01-28 2017-09-18 아스테라스 세이야쿠 가부시키가이샤 피라진카르복사마이드 화합물의 제조 방법 및 그 합성 중간체
JP6873904B2 (ja) * 2015-08-28 2021-05-19 Ils株式会社 キサンチンオキシダーゼ阻害剤
HUE052608T2 (hu) * 2015-09-02 2021-05-28 Sunshine Lake Pharma Co Ltd Karboxi-szubsztituált (hetero) aromás gyûrûs származékok, elõállítási eljárásaik és alkalmazásaik
EA037280B1 (ru) * 2015-09-10 2021-03-03 Цзянсу Атом Байосайенс Энд Фармасьютикал Ко., Лтд. Группа соединений, применяющихся для лечения или предупреждения гиперурикемии или подагры
CN107759588B (zh) * 2016-08-19 2020-10-23 江苏新元素医药科技有限公司 一类苯基-(吡唑并[1,5-a]吡啶-3-基)甲酮衍生物
BR112021001709A2 (pt) * 2018-08-01 2021-05-04 Araxes Pharma Llc compostos espiro heterocíclicos e métodos de uso dos mesmos para o tratamento de câncer
CN116438175B (zh) * 2020-11-11 2025-07-22 南京明德新药研发有限公司 苯并脲环衍生物及其制备方法和应用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201118077A (en) * 2009-10-07 2011-06-01 Lg Life Sciences Ltd Novel compounds effective as xanthine oxidase inhibitors, method for preparing the same, and pharmaceutical composition containing the same
CN115160299A (zh) * 2021-04-29 2022-10-11 江苏新元素医药科技有限公司 一类黄嘌呤氧化酶抑制剂

Also Published As

Publication number Publication date
TW202342456A (zh) 2023-11-01
CN116715633B (zh) 2025-08-12
EP4516781A1 (en) 2025-03-05
US20250282753A1 (en) 2025-09-11
JP7792730B2 (ja) 2025-12-26
JP2025514336A (ja) 2025-05-02
WO2023208108A1 (zh) 2023-11-02
EP4516781A4 (en) 2026-04-29
CN116715633A (zh) 2023-09-08

Similar Documents

Publication Publication Date Title
JP7713253B2 (ja) キサンチンオキシダーゼ抑制剤
JP2009529556A (ja) ＮＦ−κＢ阻害薬（プロテアソーム阻害薬）としてのチアゾール
RU2670088C1 (ru) Соль мангиферин-6-о-берберина, способ ее получения и применение
EP4155304B1 (en) Compound used as ret kinase inhibitor and application thereof
JP2008519049A (ja) 増殖性疾患の治療のためのｓｒｃキナーゼインヒビターおよびｂｃｒ−ａｂｌインヒビターの組み合わせ医薬
JP7792730B2 (ja) 尿酸を降下させるために使用できる化合物
CN112209886A (zh) 2-(3-氰基-4-烷氧基)苯基嘧啶衍生物及其制备方法和用途
CN106957315A (zh) N-取代苯磺酰基-氮杂吲哚氧基苯甲酰胺类化合物及其制备药物的用途
JP2025514336A5 (enExample)
CN111662239B (zh) 1,2,4-三唑类化合物及其制法和药物用途
WO2019020828A1 (en) NEW FUNCTIONALIZED PURINE-2,6-DIONES AND CORRESPONDING USE IN MEDICINE
WO2025051211A1 (zh) 用作cdk4激酶抑制剂的化合物及其应用
WO2024235218A1 (zh) Hdac1/2选择性抑制剂及其用途
TWI922802B (zh) 可用於痛風的化合物
CN113354616B (zh) 二芳基-1,2,4-三唑类化合物及其制法和药物用途
TW202448441A (zh) 脯氨醯羥化酶抑制劑及其用途
WO2024081789A2 (en) Histone demethylase inhibitors for treating cancers
WO2025237355A1 (zh) 一种glp-1受体激动剂化合物、其制备方法及其应用
WO2025185643A1 (zh) 用作cdk4蛋白激酶抑制剂的化合物及其应用
HK40090211A (en) Compound used as ret kinase inhibitor and application thereof
CN114073703A (zh) 用于治疗非酒精性脂肪肝炎的组合物和方法
WO2019072130A1 (zh) 一种1,2,4-三氮唑类化合物